MacroGenics, Inc. (MGNX) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
3.42
+19% vs avg
5yr avg: 2.88
30Y Low1.8·High9.1
ROE
↓
-86.9%
↑-55% vs avg
5yr avg: -56.2%
30Y Low-87%·High-1%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.9·High0.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MGNX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MacroGenics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $191M | $102M | $204M | $596M | $412M | $962M | $1.2B | $523M | $520M | $686M | $709M |
| Enterprise Value | $170M | $81M | $58M | $529M | $338M | $864M | $1.0B | $427M | $300M | $474M | $627M |
| P/E Ratio → | -2.55 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.27 | 0.68 | 1.37 | 10.42 | 2.75 | 12.72 | 12.26 | 8.43 | 8.65 | 4.41 | 8.19 |
| P/B Ratio | 3.42 | 1.83 | 1.75 | 3.90 | 2.90 | 4.02 | 4.05 | 2.27 | 2.14 | 2.29 | 2.64 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | 47.61 | — |
P/E links to full P/E history page with 30-year chart
MGNX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.54 | 0.39 | 9.25 | 2.25 | 11.42 | 10.71 | 6.89 | 4.98 | 3.05 | 7.24 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MGNX Profitability
Margins and return-on-capital ratios measuring operating efficiency
MacroGenics, Inc. earns an operating margin of -48.7%. Operating margins have expanded from -294.2% to -48.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -86.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 91.7% | 85.6% | 95.1% | 96.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -48.7% | -48.7% | -74.5% | -294.2% | -80.9% | -268.1% | -134.1% | -285.7% | -284.8% | -14.2% | -69.3% |
| Net Profit Margin | -49.9% | -49.9% | -45.1% | -15.8% | -79.8% | -267.2% | -132.7% | -244.8% | -285.2% | -12.6% | -67.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -86.9% | -86.9% | -49.9% | -6.1% | -62.8% | -75.5% | -49.3% | -64.1% | -63.3% | -6.9% | -20.1% |
| ROA | -28.8% | -28.8% | -23.9% | -3.1% | -38.3% | -56.6% | -37.5% | -47.1% | -48.6% | -5.7% | -17.5% |
| ROIC | -1879.3% | -1879.3% | -294.6% | -164.3% | -86.9% | -106.5% | -70.5% | -168.8% | -232.3% | -12.1% | -29.2% |
| ROCE | -34.7% | -34.7% | -49.3% | -69.6% | -48.4% | -68.9% | -44.0% | -65.7% | -57.4% | -7.3% | -19.4% |
MGNX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $57M exceeds total debt of $37M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.66 | 0.66 | 0.32 | 0.22 | 0.25 | 0.11 | 0.10 | 0.13 | — | 0.00 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.37 | -1.25 | -0.44 | -0.52 | -0.41 | -0.51 | -0.42 | -0.91 | -0.71 | -0.31 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -99.17 | -117.65 | — | — | — | — | — | — | — |
Net cash position: cash ($57M) exceeds total debt ($37M)
MGNX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
MacroGenics, Inc.'s current ratio of 5.10x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.48x to 5.10x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.10 | 5.10 | 3.92 | 4.48 | 4.57 | 3.75 | 6.17 | 5.31 | 4.49 | 6.48 | 10.40 |
| Quick Ratio | 4.92 | 4.92 | 3.92 | 4.46 | 4.54 | 3.69 | 6.17 | 5.31 | 4.49 | 6.48 | 10.69 |
| Cash Ratio | 4.40 | 4.40 | 3.63 | 4.10 | 3.18 | 3.27 | 5.38 | 4.78 | 3.88 | 6.13 | 10.15 |
| Asset Turnover | — | 0.58 | 0.57 | 0.19 | 0.52 | 0.23 | 0.26 | 0.20 | 0.18 | 0.42 | 0.28 |
| Inventory Turnover | — | — | — | 6.73 | 5.09 | 0.60 | — | — | — | — | — |
| Days Sales Outstanding | — | 32.65 | 10.60 | 66.16 | 136.79 | 50.12 | 86.17 | 75.00 | 179.60 | 32.02 | 11.65 |
MGNX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MacroGenics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $63M | $63M | $62M | $61M | $60M | $52M | $48M | $41M | $36M | $35M |
Peer Comparison
Compare MGNX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MGNXYou | $191M | -2.6 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 XNCR | $935M | -10.5 | — | — | — | — | -9.5% | — | — |
 AGEN | $137M | -1144.1 | — | — | 90.3% | -18.0% | — | — | — |
 MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
 ZYME | $2B | -25.6 | 0.3 | — | 89.8% | -87.3% | -26.7% | -25.9% | 0.0 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 AMGN | $179B | 23.3 | 14.1 | 22.1 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See MGNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MGNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MGNX vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonMGNX — Frequently Asked Questions
Quick answers to the most common questions about buying MGNX stock.
What is MacroGenics, Inc.'s P/E ratio?
MacroGenics, Inc.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
What is MacroGenics, Inc.'s ROE?
MacroGenics, Inc.'s return on equity (ROE) is -86.9%. The historical average is -41.0%.
Is MGNX stock overvalued?
Based on historical data, MacroGenics, Inc. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are MacroGenics, Inc.'s profit margins?
MacroGenics, Inc. has -48.7% operating margin.